Pasar al contenido principal

ECONOMIA DE LA PREVENCION Y ESTILOS DE VIDA. DE LA EVIDENCIA A LAS POLITICAS

ECO2013-48217-C2-1-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2013
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Secretaría de Estado de Educación, Formación Profesional y Universidades
Centro beneficiario UNIVERSIDAD DE LAS PALMAS DE GRAN CANARIA
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

El impuesto sobre bebidas azucaradas en España = Tax on sugar sweetened beverages in Spain

  • Ortún Rubio, Vicente
  • González López-Valcárcel, Beatriz
  • Pinilla Domínguez, Jaime
Este artículo aporta una revisión crítica acerca de los retos a los que se enfrentan los impuestos sobre las bebidas azucaradas como instrumento de políticas de salud, para revertir la tendencia epidémica de la obesidad. Se valoran las experiencias de los países más significados, en particular México, y se reflexiona sobre el contrapeso que ejerce la industria a las políticas antiobesidad y el poder de los lobbies. Esas políticas impositivas en pro de la salud pública han de sobreponerse a la enorme fuerza de la industria, que es ejercida en varios niveles -ciencia e investigación, reputación de marca, influencia en reguladores-. Se sugiere que un impuesto específico sobre bebidas azucaradas tiene bastante potencial para reducir enfermedades no transmisibles y riesgos -diabetes mellitus, hipertrigliceridemia, lipoproteínas de baja densidad, hipetensión diastólica-, a través de la reducción del consumo, al ser alta la elasticidad del precio de estas bebidas. Además, los efectos incluso se amplifican a medio plazo, una vez establecidos nuevos hábitos de consumo más saludable. Los impuestos podrían fomentar la innovación empresarial sin infligir costes de pérdida de empleos y contribuirían a reducir el gradiente social de la obesidad., This article provides a critical review about the challenges that taxes on sugary drinks as an instrument of health policy must face to reverse the trend of the current epidemics of obesity. We analyzed the experiences of the leading countries, particularly Mexico, and reflect on the counterweight exerted by the industry against obesity policies, and on the power of lobbyists. Those tax policies for public health have to overcome the enormous strength of the industry, which is exerted in several-science and research, brand reputation, influence on regulators-levels. We suggest that a specific tax on sugary drinks has enough potential to reduce noncommunicable diseases and risk -diabetes mellitus, hypertriglyceridemia, lipoproteins, LDL, blood pressure- via reduced consumption thanks to the high price elasticity of those drinks. Furthermore, the effects are amplified even in the medium term, once established new habits to healthier eating. These taxes could encourage business innovation without inflicting costs of lost jobs and contribute to reducing the social gradient in obesity, Este trabajo se enmarca en el proyecto ECO2013-48217-C2-1-R, Economía de la Prevención y Estilos de Vida: De la evidencia a las políticas. Plan Nacional de Investigación Orientada a los Retos de la Sociedad 2014-16 (http://invesfeps.ulpgc.es/en).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Effect of cost sharing on adherence to evidence-based medications in patients with acute coronary syndrome

  • González López-Valcárcel, Beatriz
  • Librero, Julián
  • García-Sempere, Aníbal
  • Peña, Luz María
  • Bauer, Sofía
  • Puig i Junoy, Jaume
  • Oliva, Juan
  • Peiró, Salvador, 1956-
  • Sanfélix-Gimeno, Gabriel
Objectives Cost-sharing scheme for pharmaceuticals in Spain changed in July 2012. Our aim was to assess the impact of this change on adherence to essential medication in patients with acute coronary syndrome (ACS) in the region of Valencia. Methods Population-based retrospective cohort of 10 563 patients discharged alive after an ACS in 2009–2011. We examined a control group (low-income working population) that did not change their coinsurance status, and two intervention groups: pensioners who moved from full coverage to 10% coinsurance and middle-income to high-income working population, for whom coinsurance rose from 40% to 50% or 60%. Weekly adherence rates measured from the date of the first prescription. Days with available medication were estimated by linking prescribed and filled medications during the follow-up period. Results Cost-sharing change made no significant differences in adherence between intervention and control groups for essential medications with low price and low patient maximum coinsurance, such as antiplatelet and beta-blockers. For costlier ACE inhibitor or an angiotensin II receptor blocker (ACEI/ARB) and statins, it had an immediate effect in the proportion of adherence in the pensioner group as compared with the control group (6.8% and 8.3% decrease of adherence, respectively, p<0.01 for both). Adherence to statins decreased for the middle-income to high-income group as compared with the control group (7.8% increase of non-adherence, p<0.01). These effects seemed temporary. Conclusions Coinsurance changes may lead to decreased adherence to proven, effective therapies, especially for higher priced agents with higher patient cost share. Consideration should be given to fully exempt high-risk patients from drug cost sharing., Study was funded by the Spanish State Programme of R+D+I (ECO2013-48217-C2-1-R and ECO2013-48217-C2-2-R).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

El impuesto sobre bebidas azucaradas en España = Tax on sugar sweetened beverages in Spain

  • Ortún Rubio, Vicente
  • González López-Valcárcel, Beatriz
  • Pinilla Domínguez, Jaime
Este artículo aporta una revisión crítica acerca de los retos a los que se enfrentan los impuestos sobre las bebidas azucaradas como instrumento de políticas de salud, para revertir la tendencia epidémica de la obesidad. Se valoran las experiencias de los países más significados, en particular México, y se reflexiona sobre el contrapeso que ejerce la industria a las políticas antiobesidad y el poder de los lobbies. Esas políticas impositivas en pro de la salud pública han de sobreponerse a la enorme fuerza de la industria, que es ejercida en varios niveles -ciencia e investigación, reputación de marca, influencia en reguladores-. Se sugiere que un impuesto específico sobre bebidas azucaradas tiene bastante potencial para reducir enfermedades no transmisibles y riesgos -diabetes mellitus, hipertrigliceridemia, lipoproteínas de baja densidad, hipetensión diastólica-, a través de la reducción del consumo, al ser alta la elasticidad del precio de estas bebidas. Además, los efectos incluso se amplifican a medio plazo, una vez establecidos nuevos hábitos de consumo más saludable. Los impuestos podrían fomentar la innovación empresarial sin infligir costes de pérdida de empleos y contribuirían a reducir el gradiente social de la obesidad., This article provides a critical review about the challenges that taxes on sugary drinks as an instrument of health policy must face to reverse the trend of the current epidemics of obesity. We analyzed the experiences of the leading countries, particularly Mexico, and reflect on the counterweight exerted by the industry against obesity policies, and on the power of lobbyists. Those tax policies for public health have to overcome the enormous strength of the industry, which is exerted in several-science and research, brand reputation, influence on regulators-levels. We suggest that a specific tax on sugary drinks has enough potential to reduce noncommunicable diseases and risk -diabetes mellitus, hypertriglyceridemia, lipoproteins, LDL, blood pressure- via reduced consumption thanks to the high price elasticity of those drinks. Furthermore, the effects are amplified even in the medium term, once established new habits to healthier eating. These taxes could encourage business innovation without inflicting costs of lost jobs and contribute to reducing the social gradient in obesity, Este trabajo se enmarca en el proyecto ECO2013-48217-C2-1-R, Economía de la Prevención y Estilos de Vida: De la evidencia a las políticas. Plan Nacional de Investigación Orientada a los Retos de la Sociedad 2014-16 (http://invesfeps.ulpgc.es/en).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Effect of cost sharing on adherence to evidence-based medications in patients with acute coronary syndrome

  • González López-Valcárcel, Beatriz
  • Librero, Julián
  • García-Sempere, Aníbal
  • Peña, Luz María
  • Bauer, Sofía
  • Puig i Junoy, Jaume
  • Oliva, Juan
  • Peiró, Salvador, 1956-
  • Sanfélix-Gimeno, Gabriel
Objectives Cost-sharing scheme for pharmaceuticals in Spain changed in July 2012. Our aim was to assess the impact of this change on adherence to essential medication in patients with acute coronary syndrome (ACS) in the region of Valencia. Methods Population-based retrospective cohort of 10 563 patients discharged alive after an ACS in 2009–2011. We examined a control group (low-income working population) that did not change their coinsurance status, and two intervention groups: pensioners who moved from full coverage to 10% coinsurance and middle-income to high-income working population, for whom coinsurance rose from 40% to 50% or 60%. Weekly adherence rates measured from the date of the first prescription. Days with available medication were estimated by linking prescribed and filled medications during the follow-up period. Results Cost-sharing change made no significant differences in adherence between intervention and control groups for essential medications with low price and low patient maximum coinsurance, such as antiplatelet and beta-blockers. For costlier ACE inhibitor or an angiotensin II receptor blocker (ACEI/ARB) and statins, it had an immediate effect in the proportion of adherence in the pensioner group as compared with the control group (6.8% and 8.3% decrease of adherence, respectively, p<0.01 for both). Adherence to statins decreased for the middle-income to high-income group as compared with the control group (7.8% increase of non-adherence, p<0.01). These effects seemed temporary. Conclusions Coinsurance changes may lead to decreased adherence to proven, effective therapies, especially for higher priced agents with higher patient cost share. Consideration should be given to fully exempt high-risk patients from drug cost sharing., Study was funded by the Spanish State Programme of R+D+I (ECO2013-48217-C2-1-R and ECO2013-48217-C2-2-R).